Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII…
Biotechnology
CN, Beijing [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 17.21 | -7.31 | -8.83 | |
| Graham Fair Price | 0.00 | 1.00 | 1.00 | |
| PEG | inf | 0.00 | -0.52 | |
| Price/Book | -12.45 | 0.48 | 0.55 | |
| Price/Cash Flow | 12.45 | -12.42 | -14.19 | |
| Prices/Earnings | -12.45 | 49.45 | 56.49 | |
| Price/Sales | -12.45 | 183.95 | 210.12 | |
| Price/FCF | 12.45 | -12.42 | -14.19 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 1.00 | 1.00 | |
| Operating Margin | 0.00 | -17.14 | -17.14 | |
| ROA | 0.00 | < 0.005 | < 0.005 | |
| ROE | < 0.005 | < 0.005 | 0.00 | |
| ROIC | -0.05 | -0.05 | 0.10 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | -1.00 | inf | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.04 | 0.00 | inf | |
| EPS QOQ | 1.08 | 0.00 | inf | |
| FCF QOQ | 0.32 | 0.00 | inf | |
| Revenue QOQ | -0.60 | 0.00 | inf | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.00 | < 0.005 | 100.00 | |
| Quick Ratio | 21.14 | 21.14 | 0.00 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.28 | 4.28 | 0.00 | |
| Cash | 3.65 | 3.65 | 0.00 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -0.16 | -0.16 | 0.00 | |
| Revenue | 0.01 | 0.01 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad